GE Healthcare Life Sciences Expands Cache County, Utah, Operations
12/13/2019
GE Healthcare manufactures and distributes diagnostic imaging agents and radiopharmaceuticals for imaging technologies used in medical imaging procedures. The company develops health technology for medical imaging, diagnostics, patient monitoring systems, disease research and biopharmaceutical manufacturing.
GE Healthcare may earn up to 15% of the new state taxes it will pay over the five-year life of the agreement in the form of a Utah Legislature-authorized Economic Development Tax Increment Finance (EDTIF) tax rebate. The GOED Board has approved a post-performance tax rebate not to exceed $254,554. Each year that GE Healthcare meets the criteria in its contract with the state, it will earn a portion of the total tax rebate.
“As part of our global strategy and outreach initiative, EDCUtah and GOED connected with GE Healthcare in 2018, and as a result, Governor Herbert visited company executives in Boston that summer,” said Theresa A. Foxley, president & CEO of EDCUtah. “We were excited when the local GE Healthcare management team contacted us this fall to discuss this expansion opportunity, and we’re glad to see the project come to fruition.”
“Utah has America’s most diverse economy. Adding another well-known company to the state’s life sciences roster helps to strengthen that diversity,” said Val Hale, executive director of the Governor’s Office of Economic Development. “We’re glad GE Healthcare has chosen to expand in Utah and bring more jobs to Cache County.”
Most Read
-
-
How are Uncertain Times Altering Company Location Strategies?
Q3 2020
-
2020 Gold & Silver Shovel Awards Recognize State and Local Economic Development Efforts
Q2 2020
-
Infrastructure Investment as an Economic Stimulus Tool
Q3 2020
-
2019 Top States for Doing Business: Georgia Ranks #1 Sixth Year in a Row
Q3 2019
-
34th Annual Corporate Survey & the 16th Annual Consultants Survey
Q1 2020
-
Site Selection 2020: The Importance of “Regional Depth” with Global Reach
Q3 2020